Delivery Order SPE2DB20D1004-SPE2DB25FNEBJ
Award Date
1/10/25
Potential Completion Date
1/13/25
Potential Value
$31K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $153,284 for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 4, 2023. The contract is a firm fixed-price arrangement, and there is no set-aside designation indicated.
Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $12,102.80 firm fixed price delivery order contract to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of January 29, 2024. Amerisourcebergen Drug Corp is the prime contractor and there are no set-aside designations associated with this award. This award is part of a larger $999,999,999.00 indefinite delivery contract (IDC)...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $41,926.39 order is for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 15, 2024. Amerisourcebergen Drug Corp is a for-profit organization that serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution company. The $26,025.12 firm fixed price delivery order is for the provision of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of April 4, 2024. AmerisourceBergen Drug Corp is the prime contractor and there is...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading global pharmaceutical distributor Amerisourcebergen Corporation. The $27,996.72 contract is for the supply of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing a wide range of pharmaceutical...
This federal contract award is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,361.62 fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of November 13, 2024. The contract is not designated with any set-aside requirements, indicating open competition.
AmerisourceBergen holds a...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The $18,927.36 firm fixed price delivery order has a completion date of July 12, 2024. This award is a part of a larger $999,999,999 Indefinite Delivery Contract between Amerisourcebergen and the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $16,028.23 firm fixed price delivery order is for the provision of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This contract does not have a set-aside designation.
Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and...
This federal contract award, valued at $31,939.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...